VBY-036 / Virobay - LARVOL DELTA

Spatial T1-Mapping of Cardiac Fibrosis Identifies Causal Protein Drivers through Deep Learning and Mendelian Randomization (AHA 2025) - "eQTL SMR identified LMF1 (p=8.3×10-5), JMJD6 (p=1.7×10-4), RIT1 (p=3.96×10-4). Targets with existing inhibitors include CTSS (VBY-036, RO5459072), PDE5A (sildenafil, tadalafil), and ENPP2 (ONO-8430506, PF-8380, IOA-289).Conclusions AI-derived spatial fibrosis phenotypes using VAE decomposition of T1 maps reveal hidden prognostic information and region-specific biological drivers invisible to conventional mean T1 analysis, identifying causal protein targets (FOLH1, ENPP2, CTSS, PDE5A) amenable to existing inhibitors for precision anti-fibrotic therapies."

Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Fibrosis • Heart Failure • Immunology • CTSS • DLG2 • ENPP2 • FABP4 • FOLH1 • LEP • PDE5A • RIT1 • TMPRSS6 • TNFRSF1A

TPG-backed biotech Virobay withdraws $50 million IPO (Nasdaq) - "Virobay...withdrew its plans for an initial public offering on Friday. The company originally planned to raise $50 million during the week of October 13....Virobay has completed Phase 1 trials for treatments that target neuropathic pain, Crohn's disease, and psoriasis, all of which are expected to begin Phase 2 trials in 2015."

Anticipated new P2 trial • Commercial • Inflammatory Bowel Disease • Pain • Psoriasis